Application Scenarios (Based on Existing Research Levels)
In existing public literature, research on Livagen focuses on two levels:
1. Chromatin Research at the Cellular and Molecular Level
A 2002 study by Khavinson, Lezhava, et al. demonstrated that in lymphocytes cultured in vitro from elderly individuals, Livagen could induce the activation of ribosomal genes and the decondensation of pericentromeric heterochromatin, thereby releasing genes that had been suppressed due to age-related condensation. In short, it was observed to "loosen" tightly packed chromatin, rendering previously silent gene regions accessible for transcription.
2. Liver Cell Models
A 2002 study using organotypic liver cultures reported that Livagen could stimulate structural and functional homeostasis within hepatocyte populations and enhance both cellular and intracellular regenerative processes. Other research has examined enzyme activity in the digestive tracts of rats; however, these findings are purely observational and have not been translated into human dosage or exposure data.
Key Limitations: The data mentioned above are derived exclusively from in vitro or animal models. As of 2026, there are no registered human clinical trials for Livagen or KEDA on ClinicalTrials.gov. There is no human pharmacokinetic data, no validated human dosage, and no evidence in humans of improved liver function.
Physical Mechanism
The core mechanism proposed for Livagen is the decondensation of heterochromatin. Within the cell nucleus, DNA is wrapped around histones to form chromatin; when chromatin becomes overly condensed (heterochromatinization), the genes contained within it cannot be read by the transcriptional machinery. In in vitro experiments, Livagen has demonstrated an ability to promote the decondensation of heterochromatin, thereby increasing the accessibility of specific gene regions.
While this mechanism relates to "epigenetic regulation," it differs fundamentally from the way most drugs function-typically through receptor binding or enzyme inhibition. The hypothesis is that, upon entering the cell nucleus, these short peptides alter the equilibrium of DNA-histone interactions-through a process not yet fully elucidated-allowing genes that were "switched off" by aging or pathological states to regain the potential for expression. It must be noted that this mechanism has only been observed in isolated cell systems; whether it occurs within the intact human body, at what dosage, and whether it exhibits tissue specificity remain unknown. When administered intravenously or subcutaneously, this tetrapeptide has an extremely short half-life in plasma (reportedly less than 5 minutes), raising the question of whether it can reach the cell nucleus in its intact form.
Dietary and Pharmacological Considerations
Dietary: There are no human studies providing data on dietary interactions. Given its nature as a tetrapeptide, oral administration would likely lead to degradation by gastrointestinal peptidases, resulting in extremely low and unpredictable bioavailability. Currently, there is no reliable evidence to support specific dietary combinations or recommendations regarding the timing of administration.
Pharmacological: There are no studies on drug-drug interactions. For a substance whose mechanism of action involves the regulation of gene expression, the absence of interaction data is a significant risk signal-particularly for individuals currently using prescription medications (including those metabolized by the liver or immunomodulatory agents).
Contraindications (based on the precautionary principle): Use should be avoided by pregnant or breastfeeding women, children, individuals with a history of active malignancy (due to the potential for the theoretical gene-activation mechanism to act in either a stimulatory or inhibitory manner), and those with uncontrolled liver or biliary tract disease.
Why Choose Us
While acknowledging the lack of human clinical evidence for Livagen, it is important to recognize that variations in the quality of research-grade materials represent a real and quantifiable risk. This is where the value of a primary manufacturer lies:
Direct production, not reselling. We possess in-house peptide synthesis capabilities, allowing us to control the entire process-from raw amino acid materials to the final lyophilized powder. For a tetrapeptide like Livagen (KEDA), the challenge in synthesis lies not in the length of the sequence, but in ensuring batch-to-batch consistency-a core strength of a primary manufacturer.
Professional equipment and purification processes. We utilize HPLC purification systems and LC-MS quality control platforms. Every batch of Livagen comes with purity testing (typically ≥98%) and molecular weight verification. For scientific research, sequence accuracy and purity are verifiable, objective metrics-not merely marketing rhetoric.
Stable supply. The barrier to entry for large-scale tetrapeptide synthesis is relatively low; as a primary manufacturer, we maintain regular inventory and stable lead times, ensuring your research projects are never interrupted by supply shortages.
Consistent purity and quality. We apply the same rigorous quality control (QC) standards to every batch, with a Certificate of Analysis (COA) provided for each shipment. For peptides like Livagen-which lack authoritative third-party reference standards-the manufacturer's own QC system serves as the sole benchmark for quality.
Reliable after-sales support. Should you have any questions regarding product purity or sequence, we welcome third-party verification. We stand by our products; any quality issues are addressed according to our agreement, rather than ending our responsibility the moment a sale is made.
In short: While we cannot change the fact that Livagen lacks clinical evidence in humans, we can guarantee that the raw material you use for your research is exactly what the label claims it to be, with consistent quality across every batch. In the field of scientific research reagents, this is the one aspect where there should never be any compromise.
FAQ:
Q: Where are your products manufactured?
A: Our products are manufactured in Shenzhen, China.
Q: What is the minimum order quantity (MOQ)?
A: The minimum order quantity is 10 bottles/units.
Q: How quickly do you ship after an order is placed?
A: Orders for in-stock items are dispatched within 24 hours.
Q: What purity levels do you offer?
A: Our standard purity is 99%.
Q: Which shipping carriers do you use?
A: We offer shipping via FedEx, DHL, UPS, and postal services.
Q: How long does shipping take?
A: Approximately 10–15 days.
Q: Can you provide a COA (Certificate of Analysis) and an HPLC (High-Performance Liquid Chromatography) report?
A: Yes; all products undergo professional testing before shipment.
Q: Do you offer OEM/private labeling services?
A: Yes, we provide OEM/private labeling services, subject to minimum order quantity requirements.
Q: How do you handle after-sales issues?
A: If a quality issue attributable to our production process is confirmed after you receive the goods, we offer free replacement or a full refund. We are committed to a pragmatic and responsible service approach-we address all concerns proactively and properly, without evasion or deflection, to fully protect our customers' interests. Q: What payment methods are available?
A: We accept bank transfers, Bitcoin, TransferWise, and Xoom.
Hot Tags: livagen 20mg/vial – high-purity research-grade peptide – supplier from china, China livagen 20mg/vial – high-purity research-grade peptide – supplier from china manufacturers, suppliers, factory
